Peptide-Based Inhibitors of the Hepatitis C Virus NS3 Protease: Structure-Activity Relationship at the C-Terminal Position

Journal of Medicinal Chemistry

Volumn 47, Issue 10, 2004, Pages 2511-2522

  Rancourt, Jean ^a   Cameron, Dale R ^a,b   Gorys, Vida ^a   Lamarre, Daniel ^a   Poirier, Martin ^a   Thibeault, Diane ^a   Llinàs Brunet, Montse ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^b Migenix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCYCLOPROPANECARBOXYLIC ACID DERIVATIVE; CYCLOPROPANECARBOXYLIC ACID DERIVATIVE; CYSTEINE; HEPATITIS C VIRUS NS3 PROTEASE; NORVALINE; PROTEINASE INHIBITOR; TETRAPEPTIDE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPETITIVE INHIBITION; COVALENT BOND; CRYSTAL STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HEPATITIS C VIRUS; IC 50; NONHUMAN; PROTEIN STRUCTURE; PROTEINASE INHIBITION; STRUCTURE ACTIVITY RELATION;

AMINO ACIDS, CYCLIC; CYCLOPROPANES; ENZYME INHIBITORS; HEPACIVIRUS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OLIGOPEPTIDES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 2342501873     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030573x     Document Type: Article

References (37)

1. Di Bisceglie, A. M. Hepatitis C. Lancet 1998, 351, 351-355.
2. Cohen, J. The scientific challenge of Hepatitis C. Science 1999, 285, 26-30.
3. Choo, Q.-L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a DNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989 244, 359-362.
4. Chander, G.; Sulkowski, M. S. Jenckes, M. W.; Torbenson, M. S.; Herlong, H. F.; Bass, E. B.; Gebo, K. A. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002, 36, S135-S144.
5. Houghton, M. Hepatitis C Viruses. In Fields' Virology, 3rd ed.; Fields, B. N., Knipe, D. M., Howley, P. M., Eds.; Lippincott-Raven: Philadelphia and New York, 1996; pp 1035-1058.
6. Tan, S.-L.; Pause, A.; Shi, Y.; Sonenberg, N. Hepatitis C therapeutics: current status and emerging strategies. Nat. Rev. Drug Discovery 2002, 1, 867-881.
7. Di Bisceglie, A. M.; McHutchison, J.; Rice, C. M. New therapeutic strategies for hepatitis C. Hepatology 2002, 35, 224-231.
8. Reed, K. E.; Rice, C. M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 2000, 242, 55-84.
9. Kwong, A. D.; Kim, J. L.; Rao, G.; Lipovsek, D.; Raybuck, S. A. Hepatitis C virus NS3/4A protease. Antiviral Res. 1998, 40, 1-18.
10. De Francesco, R.; Steinkühler, C. Structure and function of the Hepatitis C virus NS3-NS4A proteinase. Curr. Top. Microbiol. Immunol. 2000, 242, 149-169.
11. Kolykhalov, A. A.; Mihalik, K.; Feinstone, S. M.; Rice, C. M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 2000, 74, 2046-2051.
12. Llinàs-Brunet, M.; Bailey, M.; Fazal, G.; Goulet, S.; Halmos, T.; LaPlante, S.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Thibeault, D.; Wernic, D.; Lamarre, D. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 1998, 8, 1713-1718.
13. Steinküler, C.; Biasiol, G.; Brunetti, M.; Urbani, A.; Koch, U.; Cortese, R.; Pessi, A.; De Francesco, R. Product inhibition of the Hepatitis C virus NS3 protease. Biochemistry 1998, 37, 8899-8905.
14. For a protease subsite nonmenclature, see: Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27, 157.
15. (a) Llinàs-Brunet, M.; Bailey, M.; Fazal, G.; Ghiro, E.; Gorys, V.; Goulet, S.; Halmos, T.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Rancourt, J.; Thibeault, D.; Wernic, D.; Lamarre, D. Studies on the C-terminal of hexapeptide inhibitors of the Hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 1998, 8, 2719-2724.
16. (b) Llinàs-Brunet, M.; Bailey, M.; Fazal, G.; Ghiro, E.; Gorys, V.; Goulet, S.; Halmos, T.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Rancourt, J.; Thibeault, D.; Wernic, D.; Lamarre, D. Highly potent and selective peptide-based inhibitors of the Hepatitis C virus serine protease: towards smaller inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 2267-2270.
17. (c) LaPlante, S. R.; Aubry, N.; Bonneau, P. R.; Kukolj, G.; Lamarre, D.; Lefebvre, S.; Li, H.; Llinàs-Brunet, M.; Plouffe, C.; Cameron, D. NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the Hepatitis C virus NS3 protease domain. Bioorg. Med. Chem. Lett. 2000, 10, 2271-2274.
18. 50 value for compound 1 in ref 15b (3.5 μM) compared to ours (14 μM) comes from the fact that two different assays were used (the details of the first assay can be found in ref 12 and, for the second one, in the Experimental Section of the present article).
19. 1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease. Bioorg. Med. Chem. Lett. 2002, 701-704.
20. (b) Colarusso, S.; Gerlach, B.; Koch, U.; Muraglia, E.; Conte, I.; Stansfield, I.; Matassa, V. G.; Narjes, F. Evolution, synthesis and SAR of tripeptide α-ketoacid inhibitors of the Hepatitis C virus NS3/NS4A serine protease. Bioorg. Med. Chem. Lett. 2002, 705-708.
21. Yao, N.; Reichert, P.; Taremi, S. S.; Prosise, W. W.; Weber, P. C. Molecular views of viral polyprotein processing revealed by the crystal structure of the Hepatitis C virus bifunctional protease-helicase. Structure, 1999, 7, (11), 1353-1363.
22. (a) Burgess, K.; Ho, K.-K. Asymmetric syntheses of all four stereoisomers of 2,3-methanomethionine. J. Org. Chem. 1992, 57, 5931-5936.
23. (b) Burgess, K.; Li, W. Tetrahedron Lett. 1995, 36, 2725-2728.
24. (c) Burgess, K.; Ke, C.-Y. Large scale syntheses of N-protected 2,3-methanomethionine stereoisomers. Synthesis 1999, 1463-1467.
25. Baldwin, J. E.; Adlington, R. M.; Rawlings, B. J. A convenient synthesis of region-specifically 2-alkylated-3-deuteriated-1-aminocyclopropane-1-carboxylic acids. Tetrahedron Lett. 1985, 26, 481-484.
26. Gassman, P. G.; Schenk, W. N. A general procedure for the base-promoted hydrolysis of hindered esters ar ambient temperature. J. Org. Chem. 1977, 42, 918-920.
27. Capson, T. L.; Poulter, C. D. A facile synthesis of primary amines from carboxylic acids by the curtius rearrangement. Tetrahedron Lett. 1984, 25, 3515-3518.
28. Verhé, R.; De Kimpe, N.; De Buyck, L.; Courtheyn, D.; Schamp, N. Preparation of 2,2-dialkylcyclopropanes geminally substituted with electron-withdrawing groups. Synthesis 1978, 530-532.
29. Charette, A. B.; Côté, B. Stereoselective synthesis of all four isomers of coronamic acid: a general approach to 3-methanoamino acids. J. Am. Chem. Soc. 1995, 117, 12721-12732. We thank professor Charette who kindly provided us with a sample of compound 13 in a homochiral form.
30. Gibson, F. S.; Bergmeier, S. C.; Rapoport, H. Selective removal of an N-Boc protecting group in the presence of a tert-butyl ester and other acid-sensitive groups. J. Org. Chem. 1994, 59, 3216-3218.
31. Poupart, M.-A.; Cameron, D. R.; Chabot, C.; Ghiro, E.; Goudreau, N.; Goulet, S.; Poirier, M.; Tsantrizos, Y. Solid-phase synthesis of peptidomimetic inhibitors for the Hepatitis C virus NS3 protease. J. Org. Chem. 2001, 66, 4743-4751.
32. 50 values for compounds 26 and 27 in ref 25 compared to ours come from the fact that two assay methods (fluorogenic vs radiometric) with different substrates were used.
33. The enzymatic resolution of vinyl-ACCA has been performed successfully. Details regarding the resolution of ACCA derivatives will be reported elsewhere. The absolute configuration at C1 and C2 on the cyclopropane ring of vinyl-ACCA was established by hydrogenation of the unsaturation and comparison with the corresponding ethyl-ACCA derivative for which the structure had been proven (see Scheme 3).
34. Orvieto, F.; Koch, U.; Matassa, V. G.; Muraglia, E. Novel, potent phenrthylamide inhibitors of the Hepatitis C virus (HCV) NS3 protease: probing the role of P2 aryloxyprolines with hybrid structures. Bioorg. Med. Chem. Lett. 2003, 2745-2748.
35. Dixon, E. A.; Fischer, A.; Robinson, F. P. Preparation of a series of substituted fluoromethylnaphthalenes. Can. J. Chem. 1981, 59, 2629-2641.
36. Yan, Y.; Li, Y.; Munshi, S.; Sardana, V.; Cole, J. L.; Sardana, M.; Steinkuehler, C.; Tomei, L.; De Franscesco, R.; Kuo, L. C. Chen, Z. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 A resolution structure in a hexagonal crystal form. Protein Sci. 1998, 7, 837-847.
37. Pause, A.; Kukolj, G.; Bailey, M.; Dô, F.; Halmos, T.; Lagacé, L.; Maurice, R.; Marquis, M.; McKercher, G.; Pellerin, C.; Pilote, L.; Thibeault, D.; Lamarre, D. An NS3 serine protease inhibitor abrogates replication of subgenomic Hepatitis C Virus RNA. J. Biol. Chem. 2003, 278, 20374-20380.